INSM
$136.00-8.00 (-5.56%)
Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial l...
Recent News
How Insmed (INSM) Is Rewriting Its Story Around Brinsupri And 2026 Expectations
Insmed’s fair value estimate has been fine tuned, with the modeled price target edging from US$212.53 to US$213.00, signaling only a very modest shift in the equity story. That small adjustment lines up with recent Street commentary, where analysts are broadly constructive on Brinsupri and bronchiectasis, yet are carefully updating targets while keeping an eye on execution and sector risks. As you read on, you will see how to track these incremental changes and what they may mean for Insmed’s...
This Specialized Heart Monitor Maker Just Caught the Eye of a Major Healthcare Fund
RTW Investments loads up on iRhythm Holdings with 1.18M Shares Worth $210 million. iRhythm delivers wearable cardiac monitoring and analytics solutions to healthcare providers and at-risk patients.
Brensocatib Approval Gives Insmed New Growth Pillar And Valuation Gap
Insmed's Brensocatib has received its first approval as a treatment for non cystic fibrosis bronchiectasis. The product launch has led to significant initial sales, signaling early commercial traction. This marks the first approved therapy for this condition, addressing an area of unmet medical need. For Insmed, listed as NasdaqGS:INSM, the approval of Brensocatib comes at a time when the share price is $144.0. The stock has seen a 3.2% return over the past week and is up 82.8% over the...
This $91 Million Position Signals Conviction in a Biotech Stock Eyeing FDA Decision This Year
This clinical-stage biotech develops therapies for serious immunological diseases, with a focus on late-stage biologic candidates.
Artisan Small Cap Fund Sold Insmed (INSM) on Valuation Consideration
Artisan Partners, an investment management company, released its fourth-quarter 2025 investor letter for “Artisan Small Cap Fund”. A copy of the letter can be downloaded here. The Fund seeks to invest in companies that possess franchise characteristics, with strong earnings trajectories, and are trading at a discount to the estimated private market value. Despite strong results […]